The National Health Surveillance Agency (ANVISA) authorized on Friday (4th) the import of the experimental medication ALN-6457, developed by pharmaceutical company Regeneron Pharmaceuticals, for the treatment of digital influencer Lito Sousa. The decision was considered exceptional, given that the company does not have a legal representative in Brazil and the drug does not have commercial registration with the regulatory agency.
Lito Sousa lives with Creutzfeldt-Jakob disease, a rare and rapidly progressive neurological disease. The agency took into consideration the progressive nature of the disease when authorizing the import of the medication, which is in the pre-clinical study phase, meaning it has not yet been tested in humans with the influencer's condition.
The import request was made by Hospital Israelita Albert Einstein, after Lito was accepted for use of the experimental treatment. According to Mila Seidl, the influencer's wife, the expectation is that the medication will arrive in Brazil within 7 to 9 days. She celebrated the news on social media, stating that "the impossible is becoming reality" and that the couple is ready to receive the treatment.
